Results 131 to 140 of about 78,382 (206)

Cardiotoxicity of BRAF/MEK Inhibitors

JACC: CardioOncology, 2023
Claire Glen, Sarah Adam, Kirsty McDowell, Ashita Waterston, Yun Yi Tan, Mark C. Petrie, Caroline J. Coats, Ninian N. Lang   +7 more
openaire   +1 more source

Machine learning-based pan-cancer study of classification and mechanism of BRAF inhibitor resistance. [PDF]

Transl Cancer Res
Zhao Y, Yang K, Chen Y, Lv Z, Wang Q, Zhong Y, Chen X.   +6 more
europepmc   +1 more source

BRAF Inhibitor Therapy-Related Encephalitis in a Patient with Metastatic Melanoma. [PDF]

Oncologist, 2021
Babacan NA, Peguero E, Forsyth P, Eroglu Z.   +3 more
europepmc   +1 more source

Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents [PDF]

, 2017
Abraham, Christopher, Acharya, Sahaja, Chicoine, Michael, Dowling, Joshua, Dunn, Gavin, Huang, Jiayi, Keller, Jesse, Leuthardt, Eric, Mahmood, Mustafaa, Mullen, Daniel, Perkins, Stephanie M, Rich, Keith, Robinson, Clifford G, Tsien, Christina I, Yang, Deshan   +14 more
core   +2 more sources

NAMPT and NNMT released via extracellular vesicles and as soluble mediators are distinguished traits of BRAF inhibitor resistance of melanoma cells impacting on the tumor microenvironment. [PDF]

Cell Commun Signal
Ghezzi B, Fiorilla I, Carreira Á, Recco F, Sorci L, Avalle L, Ponzano A, Mazzola F, Todesco AM, Tommasi N, Gasparrini M, D'Agostino VG, Mignone F, Provenzani A, Audrito V.   +14 more
europepmc   +1 more source

Addendum: Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report. [PDF]

Oncotarget, 2023
Rao M, Bhattacharjee M, Shepard S, Hsu S.   +3 more
europepmc   +1 more source

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives

Cancer Management and Research
Michelle M Dugan,1 Matthew C Perez,1 Lilit Karapetyan,1,2 Jonathan S Zager1,2 1Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA; 2Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL,
Dugan MM, Perez MC, Karapetyan L, Zager JS   +3 more
doaj  

Endocrine effects of MEK and BRAF inhibitor therapy in paediatric patients: a tertiary centre experience. [PDF]

J Neurooncol
Jalal AHB, Gunn H, Gunasekara B, Gan HW.
europepmc   +1 more source

BRAF inhibitor treatment of classical hairy cell leukemia allows successful vaccination against SARS-CoV-2. [PDF]

Ann Hematol, 2023
Konrat J, Rösler W, Roiss M, Meier-Abt F, Widmer CC, Balabanov S, Manz MG, Zenz T.   +7 more
europepmc   +1 more source

Second-generation BRAF inhibitor Encorafenib resistance is regulated by NCOA4-mediated iron trafficking in the drug-resistant malignant melanoma cells. [PDF]

Sci Rep
Colakoglu Bergel C, Eryilmaz IE, Cecener G, Egeli U.   +3 more
europepmc   +1 more source